Major depressive disorder (MDD) is a disturbance of mood that may have persistent and long-term consequences impacting patients’ overall level of functioning and quality of life. 1 Historically, ...

Accelerated repetitive transcranial magnetic stimulation appears to be effective for treatment-resistant depression.

Credit: Otsuka. At this time, the product is available to patients for a discounted price of $50; the full price is $200. Rejoyn ™, the first prescription digital therapeutic cleared for the treatment ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

DMT therapy significantly reduced major depressive disorder symptoms in a phase IIa trial. Learn more about this rapid-acting psychedelic approach.

Seltorexant is an investigational selective antagonist of the human orexin-2 receptor. Seltorexant, an investigational selective orexin-2 receptor antagonist, was associated with statistically ...

A single dose of the psychedelic drug dimethyltryptamine (DMT), given with psychological support, rapidly reduced depressive ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Neumora Therapeutics, Inc. (NMRA) is gearing up to report results from one of its phase 3 studies, which is using its drug Navacaprant for the treatment of patients with major depressive disorder (MDD ...

Mood symptoms alone do not account for the extent of disability associated with MDD. 12 Cognitive impairment, 1 of the 9 core symptoms of MDD (see Table 1), is significantly associated with impaired ...